These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8474372)

  • 1. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
    Smith RD; Hall J; Gurney H; Harnett PR
    Med J Aust; 1993 Mar; 158(5):319-22. PubMed ID: 8474372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
    de Souza P
    Med J Aust; 1993 Jun; 158(12):866. PubMed ID: 8326905
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
    Monz BU; König HH; Leidl R; Staib L; Link KH
    Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis.
    Norum J; Vonen B; Olsen JA; Revhaug A
    Ann Oncol; 1997 Jan; 8(1):65-70. PubMed ID: 9093709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
    Wolmark N; Rockette H; Mamounas E; Jones J; Wieand S; Wickerham DL; Bear HD; Atkins JN; Dimitrov NV; Glass AG; Fisher ER; Fisher B
    J Clin Oncol; 1999 Nov; 17(11):3553-9. PubMed ID: 10550154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
    Bleeker WA; Mulder NH; Hermans J; Otter R; Plukker JT
    Ann Oncol; 2000 May; 11(5):547-52. PubMed ID: 10907947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic overview of chemotherapy effects in colorectal cancer.
    Ragnhammar P; Hafström L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
    Cassidy J; Douillard JY; Twelves C; McKendrick JJ; Scheithauer W; Bustová I; Johnston PG; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan TS; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel KK; Cowell W; Garrison LP
    Br J Cancer; 2006 Apr; 94(8):1122-9. PubMed ID: 16622438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
    Moertel CG; Fleming TR; Macdonald JS; Haller DG; Laurie JA; Tangen CM; Ungerleider JS; Emerson WA; Tormey DC; Glick JH
    J Clin Oncol; 1995 Dec; 13(12):2936-43. PubMed ID: 8523058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
    Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
    Elsaleh H; Powell B; Soontrapornchai P; Joseph D; Goria F; Spry N; Iacopetta B
    Oncology; 2000; 58(1):52-9. PubMed ID: 10644941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
    Alarid-Escudero F; Schrag D; Kuntz KM
    Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04).
    Mamounas E; Wieand S; Wolmark N; Bear HD; Atkins JN; Song K; Jones J; Rockette H
    J Clin Oncol; 1999 May; 17(5):1349-55. PubMed ID: 10334518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
    World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment of node-positive colon carcinoma with levamisole and 5-fluorouracil.
    Grem JL
    Oncology (Williston Park); 1991 Mar; 5(3):63-70, 73; discussion 73-4. PubMed ID: 1829947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant chemotherapy improves chances of survival in curative surgery of colon cancer, Dukes' stage C].
    Porschen R; Stremmel W
    Z Gastroenterol; 1990 Jul; 28(7):375-6. PubMed ID: 2238769
    [No Abstract]   [Full Text] [Related]  

  • 19. Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.
    Tsavaris N; Gennatas K; Kosmas C; Skopelitis HM; Gouveris P; Dimitrakopoulos A; Zacharakis M; Kouraklis G; Vasiliou J; Felekouras E; Voros D; Zografos G; Balafouta M; Paraskevaidis M; Safioleas M; Fotiadis K; Papastratis G; Karatzas G; Papalambros E
    Oncol Rep; 2004 Oct; 12(4):927-32. PubMed ID: 15375524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of fluorouracil + folinic acid, fluorouracil + levamisole and fluorouracil + folinic acid + levamisole in Dukes' B and C colon cancer: NSABP Trial C-04].
    Schumacher K
    Strahlenther Onkol; 2000 May; 176(5):239-40. PubMed ID: 10847122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.